List of Excipients in Branded Drug VORANIGO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Servier Pharmaceuticals LLC	VORANIGO	vorasidenib	72694-879	CELLULOSE, MICROCRYSTALLINE	2034-07-11
Servier Pharmaceuticals LLC	VORANIGO	vorasidenib	72694-879	CROSCARMELLOSE SODIUM	2034-07-11
Servier Pharmaceuticals LLC	VORANIGO	vorasidenib	72694-879	FERROSOFERRIC OXIDE	2034-07-11

Voranigo Excipient Strategy and Commercial Opportunities

Last updated: August 30, 2026

Voranigo (vorasidenib) is a once-daily oral tablet approved by the FDA for adults and children aged 12 years and older with grade 2 astrocytoma or oligodendroglioma carrying susceptible IDH1 or IDH2 mutations after surgery. Its excipient platform is conventional, which lowers manufacturing complexity but creates commercial opportunities in pediatric delivery, swallowability, dose flexibility, stability, and generic substitution control.[1][2]

The principal commercial opportunity is not a new active pharmaceutical ingredient. It is the development of differentiated oral presentations and excipient systems that address long-term treatment, adolescent use, swallowing difficulty, adherence, and generic lifecycle competition.

What is Voranigo and how is it administered?

Voranigo contains vorasidenib, a small-molecule inhibitor of mutant IDH1 and IDH2 enzymes. The approved product is an oral tablet taken once daily, with 10 mg and 40 mg strengths.[1]

Product attribute	Voranigo information
Active ingredient	Vorasidenib
Brand owner	Servier Pharmaceuticals LLC
FDA approval	August 6, 2024
Therapeutic area	IDH-mutant grade 2 glioma
Approved population	Adults and pediatric patients aged 12 years and older
Dosage form	Oral tablet
Strengths	10 mg and 40 mg
Administration	Once daily
Food instruction	May be taken with or without food
Key safety monitoring	Hepatotoxicity, liver enzyme elevations, embryo-fetal toxicity
Regulatory pathway	NDA approval
Biosimilar exposure	None; vorasidenib is a small molecule

Voranigo is intended for a patient population that may remain on therapy for an extended period. That makes tablet robustness, consistent dissolution, tolerability, and adherence more commercially relevant than rapid-onset performance.

What excipients are used in Voranigo tablets?

The FDA prescribing information identifies conventional tablet and film-coating excipients. The listed inactive ingredients include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, talc, titanium dioxide, and polyethylene glycol.[1]

Excipient	Likely functional role	Commercial relevance
Lactose monohydrate	Diluent and tablet-mass contributor	Supports direct compression and cost-efficient manufacturing
Microcrystalline cellulose	Diluent, dry binder, compressibility aid	Helps produce mechanically robust tablets
Croscarmellose sodium	Superdisintegrant	Supports tablet breakup and dissolution
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and blend uniformity
Magnesium stearate	Lubricant	Reduces sticking and ejection force
Polyvinyl alcohol	Film-forming coating polymer	Protects the tablet and supports appearance
Talc	Coating aid and anti-tacking agent	Improves coating performance
Titanium dioxide	Opacifier and colorant	Provides film-coat opacity
Polyethylene glycol	Plasticizer in the film coat	Improves coating flexibility

The formulation indicates a conventional immediate-release platform rather than a modified-release, lipid-based, amorphous solid-dispersion, or gastroretentive system.

How does the Voranigo excipient platform affect manufacturing?

The current excipient system is compatible with a standard high-volume tablet process. A likely manufacturing sequence is dispensing, dry blending, lubrication, compression, and aqueous or solvent-based film coating. The precise commercial process is proprietary, but the excipient selection is consistent with direct-compression or low-shear dry-granulation approaches.

Three manufacturing issues will drive cost and quality performance.

Blend uniformity at relatively low drug loading

The 10 mg tablet creates greater blend-uniformity pressure than the 40 mg tablet. Colloidal silicon dioxide and microcrystalline cellulose can improve flow, but over-lubrication with magnesium stearate can reduce tablet hardness and slow dissolution.

For generic manufacturers, the 10 mg strength may require tighter control of particle-size distribution, segregation, order of addition, and lubrication time. A formulation that performs well at 40 mg may not transfer directly to the lower strength.

Moisture management

Lactose, croscarmellose sodium, microcrystalline cellulose, and film-coating components can respond differently to humidity. Moisture can affect powder flow, tablet hardness, disintegration, and long-term dissolution. Commercial excipient suppliers can compete through low-moisture grades, tighter water-activity specifications, and documented lot-to-lot consistency.

Tablet coating and visual differentiation

The film coat supports mechanical protection and product identification. Coating suppliers can compete through ready-to-use systems that reduce process development time, improve color consistency, and limit coating defects. For a chronic oncology product, tablet appearance and ease of identification can support medication-error reduction.

What excipient strategies could improve Voranigo lifecycle management?

The strongest lifecycle opportunities involve administration and adherence rather than changing the drug's pharmacology.

Pediatric-friendly solid dosage forms

The FDA approval includes patients aged 12 years and older. That age range includes adolescents who may have difficulty swallowing conventional tablets or who require flexible dosing during growth or treatment adjustment.

Potential development paths include:

• Orally disintegrating tablets
• Mini-tablets
• Multiparticulate sprinkle products
• Taste-masked granules
• A powder for oral suspension
• A lower-strength tablet for dose titration

Any new presentation would require comparative bioavailability, dose uniformity, stability, palatability, and administration studies. A liquid or dispersible product would also require controls for settling, wetting, redispersion, microbial quality, and dose-measuring accuracy.

Swallowability and tablet size reduction

The current 40 mg product may be suitable for adult dosing, but a smaller tablet could improve adherence for patients with neurologic disease, postoperative impairment, or treatment-related fatigue. Commercially useful approaches include higher drug loading, co-processed excipients, roller compaction, and optimized compression tooling.

A size-reduced tablet must preserve dissolution and mechanical strength. Highly compactable grades of microcrystalline cellulose, silicified microcrystalline cellulose, mannitol, and co-processed excipient systems could compete with the current platform.

Lactose-free or low-lactose alternatives

The marketed formulation uses lactose monohydrate. A lactose-free formulation could target patients with lactose intolerance or reduce excipient-related screening concerns in global markets. Possible replacements include mannitol, dibasic calcium phosphate, starch derivatives, or co-processed polyols.

The commercial value of a lactose-free version is likely incremental rather than transformative because lactose intolerance does not automatically preclude use of the low-dose lactose present in a tablet. The opportunity is stronger where a sponsor wants a differentiated formulation for pediatric, hospital, or international markets.

Improved moisture and stability control

A moisture-resistant formulation could support hot and humid markets, reduce packaging requirements, and improve supply-chain flexibility. Options include:

• Low-moisture excipient grades
• Protective film coatings
• High-barrier blister packaging
• Desiccant-based bottle systems
• Moisture-scavenging packaging
• Alternative disintegrants with lower hygroscopicity

Packaging changes may provide a lower-risk commercial improvement than a new formulation patent because they can address stability without changing the drug product composition.

What formulation patents could protect a Voranigo product?

Formulation patents could cover a distinct excipient combination, manufacturing process, particle-size distribution, solid-state form, dissolution profile, or dosage form. Potential claim areas include:

Patent strategy	Potential subject matter	Commercial purpose
Composition patent	Vorasidenib with a defined excipient ratio	Protects a differentiated tablet formulation
Solid-state patent	Crystalline or amorphous vorasidenib form	Controls API supply and generic design-around risk
Process patent	Granulation, blending, compression, or coating conditions	Protects manufacturing know-how
Pediatric formulation patent	Taste-masked liquid, granule, or dispersible dosage form	Extends product reach to younger patients
Stability patent	Moisture-control composition or packaging combination	Supports geographic expansion
Method-of-use patent	Use in a defined IDH-mutant glioma population	Protects a clinical-use segment
Device or administration patent	Dose-measuring or dispersion system	Supports differentiated administration

The strongest formulation claims generally require a measurable technical effect, such as improved stability, dissolution, bioavailability, dose uniformity, or palatability. A simple substitution of one conventional filler for another may face obviousness challenges unless the change produces an unexpected result.

What is the Orange Book and patent status of Voranigo?

Voranigo is an NDA-approved small molecule and is eligible for Orange Book listing. The FDA approval itself does not establish the complete commercial exclusivity period. The applicable protection depends on listed patents, five-year new chemical entity exclusivity, pediatric extensions, any qualified infectious disease provisions, and the timing of ANDA or 505(b)(2) filings.[2][3]

Protection category	Relevance to Voranigo
New chemical entity exclusivity	Potentially relevant because vorasidenib is a new active ingredient approved in the U.S.
Orange Book patents	May cover drug substance, formulation, method of use, or approved dosage form
Paragraph IV challenge	Possible after ANDA applicants identify listed patents as invalid, unenforceable, or not infringed
Pediatric extension	Could add six months if applicable regulatory requirements are completed
Biosimilar pathway	Not applicable
505(b)(2) competition	Relevant for materially different oral formulations or delivery systems
ANDA competition	Relevant for conventional immediate-release tablets

The commercial protection profile should be evaluated at the individual patent-claim level. A composition-of-matter patent generally creates the largest barrier to conventional generic entry. Formulation and method-of-use patents can still affect launch timing, but their value depends on claim breadth, approved-label overlap, and litigation outcomes.

When could generic manufacturers challenge Voranigo?

Generic manufacturers can pursue an ANDA for the 10 mg and 40 mg tablets if they can demonstrate pharmaceutical equivalence, bioequivalence, manufacturing quality, and labeling compliance. A Paragraph IV certification may challenge listed patents before their stated expiration dates.

The most likely generic strategy is a conventional immediate-release tablet using a different but functionally equivalent excipient system. Potential design-around substitutions include:

• Lactose replaced by mannitol or dibasic calcium phosphate
• Microcrystalline cellulose replaced by a different compressible diluent
• Alternative superdisintegrants
• Different coating polymers and pigments
• Modified lubricant or glidant levels

The major technical barriers are low-dose content uniformity, dissolution matching, stability, and analytical method transfer. The major legal barriers are active-ingredient and formulation patents, as well as any enforceable method-of-use patents that would be implicated by the proposed label.

What generic entry risks exist for Voranigo?

Generic entry risk is moderate over the long term because Voranigo is a small molecule administered as a conventional tablet. The formulation does not appear to rely on a complex delivery system that would be difficult to reproduce.

Risk factors favoring generic entry include:

• Conventional oral solid dosage form
• No biologic manufacturing barrier
• No injectables or device combination
• Standard tablet excipients
• Two strengths that can be developed within one platform

Risk factors supporting originator protection include:

• New chemical entity exclusivity
• Potential composition-of-matter protection
• Specialized oncology indication
• Low-dose blend-uniformity requirements
• Clinical and regulatory complexity surrounding IDH-mutant glioma labeling
• Potentially narrow but commercially important patient population

A generic manufacturer may initially target the 40 mg strength because higher drug loading simplifies content-uniformity control. The 10 mg strength may follow after process experience is established.

Which companies could compete in Voranigo excipients?

The marketed excipient classes are supplied by a large, competitive global base. Commercial opportunities exist for both multinational excipient manufacturers and specialty suppliers.

Relevant supplier categories include:

Excipient category	Competitive product characteristics
Microcrystalline cellulose	Compressibility, low moisture, particle-size control
Lactose	Direct-compression performance, low endotoxin and low bioburden grades
Superdisintegrants	Fast breakup, low use level, compatibility with low-dose tablets
Colloidal silica	Flow improvement and moisture-control performance
Magnesium stearate	Consistent lubrication with limited dissolution impact
Film-coating systems	Ready-to-use coating, color consistency, reduced process time
Co-processed excipients	Better flow, compactability, and reduced formulation development time
Taste-masking systems	Compatibility with liquid, granule, or orally disintegrating presentations

The strongest supplier opportunity is a validated co-processed excipient platform that improves 10 mg content uniformity while reducing tablet size and maintaining rapid dissolution.

How large is the commercial opportunity for Voranigo excipient innovation?

The opportunity is linked to treatment duration and expansion of the treated population. The INDIGO phase 3 trial demonstrated that vorasidenib improved progression-free survival and delayed the next intervention compared with placebo in patients with grade 2 IDH-mutant glioma.[4]

Longer treatment duration increases the value of:

• Low-pill-burden dosage forms
• Stable global supply
• Pediatric-friendly administration
• Reduced tablet defects and manufacturing waste
• Differentiated formulations for licensing
• Second-source excipient qualification

The addressable excipient market is smaller than the active-drug market, but it can generate strategic value through formulation licensing, supply contracts, co-development, and patent-backed lifecycle products.

Potential commercial models include:

1. Supplying qualified excipients to the originator or contract manufacturer.
2. Licensing a co-processed direct-compression platform.
3. Developing a pediatric dispersible or liquid formulation.
4. Providing high-barrier packaging and stability solutions.
5. Supporting a generic manufacturer with a bioequivalence-ready formulation.
6. Creating a 505(b)(2) product with improved administration characteristics.

How does Voranigo compare with competing IDH inhibitors?

Voranigo has a distinct commercial position because it is approved for grade 2 IDH-mutant glioma, while other IDH inhibitors have different disease settings or development status.

Drug	Active ingredient	Primary commercial setting	Excipient opportunity
Voranigo	Vorasidenib	Grade 2 IDH-mutant astrocytoma or oligodendroglioma	Pediatric, swallowability, long-term oral adherence
Tibsovo	Ivosidenib	IDH1-mutant cancers, including AML and cholangiocarcinoma	Tablet-size reduction, stability, generic platform development
Idhifa	Enasidenib	IDH2-mutant AML	Chronic oral dosing and formulation substitution
Experimental IDH inhibitors	Various	Hematologic and solid tumors	Formulation differentiation and clinical-development support

Voranigo’s key formulation distinction is its use in a relatively young population with a chronic neurologic cancer. That profile makes administration and adherence more important than in many acute oncology indications.

What regulatory requirements apply to a new Voranigo formulation?

A reformulated product would require a regulatory strategy matched to the extent of change.

A line extension using the same active ingredient could potentially rely on a 505(b)(2) application if it introduces a new dosage form, route, strength, or formulation. A conventional generic tablet would generally use the ANDA pathway. A pediatric liquid or dispersible product would require evidence addressing dose delivery, stability after preparation, palatability, and bioequivalence.

Key development studies include:

• Comparative dissolution across relevant pH conditions
• Single-dose pharmacokinetic bioequivalence
• Content uniformity and assay
• Forced degradation and photostability
• Extractables and leachables for liquid systems
• In-use stability for reconstituted or opened products
• Compatibility with feeding tubes if claimed
• Pediatric acceptability and administration studies

Key Takeaways

• Voranigo is a once-daily, immediate-release vorasidenib tablet approved for IDH-mutant grade 2 glioma.
• The marketed excipient system uses conventional diluents, disintegrants, glidants, lubricants, and film-coating materials.
• The highest-value formulation opportunities are pediatric delivery, improved swallowability, lower tablet burden, moisture control, and lactose-free alternatives.
• A co-processed excipient platform could improve 10 mg content uniformity and reduce tablet size.
• Generic competition is technically feasible because Voranigo is a conventional small-molecule tablet.
• Composition-of-matter patents and new chemical entity exclusivity are likely to be more important than conventional excipient patents for early market protection.
• No biosimilar pathway applies to vorasidenib.
• Licensing opportunities are strongest in differentiated oral dosage forms, supply qualification, and 505(b)(2) lifecycle products.

FAQs

Can Voranigo be compounded into a liquid?

The approved product is a tablet. A compounded liquid would require validated stability, uniformity, dose-measurement, and administration data. An authorized pediatric liquid would require a separate regulatory submission.

Is lactose in Voranigo tablets?

Yes. The FDA label lists lactose monohydrate as an inactive ingredient.[1]

Could a generic Voranigo use different excipients?

Yes. An ANDA applicant can generally use different inactive ingredients if the proposed product meets applicable pharmaceutical equivalence, bioequivalence, quality, and safety requirements.

Does Voranigo have biosimilar competition?

No. Vorasidenib is a small molecule, so competition would arise through generic or 505(b)(2) pathways rather than biosimilar applications.

What is the most attractive excipient business opportunity linked to Voranigo?

A pediatric-friendly, taste-masked, dispersible, or liquid formulation is the most differentiated opportunity. A co-processed tablet excipient for low-dose uniformity is the strongest near-term manufacturing opportunity.

References

1. U.S. Food and Drug Administration. (2024). Voranigo (vorasidenib) tablets: Prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024, August 6). FDA approves vorasidenib for Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. FDA.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
4. Mellinghoff, I. K., Penas-Prado, M., Peters, K. B., et al. (2023). Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. New England Journal of Medicine, 389(7), 589-601. https://doi.org/10.1056/NEJMoa2304194